This bill would direct the Secretary of Health and Human Services to run a national, evidence-based education campaign about the risks and benefits of human cell and tissue products transplants. The campaign would be aimed at both the public and health care providers, with the goal of improving informed decision-making and safer use of these products. It is a federal health-education measure rather than a benefit program or spending entitlement, so its main effect would come through guidance, outreach, and awareness efforts. The bill was introduced in the Senate and referred to the Senate Health, Education, Labor, and Pensions Committee.
What This Bill Does
- Directs HHS to run a national education campaign
- Campaign must be evidence-based
- Focuses on both public awareness and provider education
- Covers the risks and benefits of human cell and tissue products transplants
- Referred to the Senate HELP Committee after introduction
Who This Bill Affects
If you are a patient considering a procedure involving human cell or tissue products, this bill could improve the quality of information you receive from doctors or clinics and make it easier to understand potential risks and benefits before consenting. If you are a clinician, hospital, or transplant-related provider, it could mean more federal educational materials and possibly new expectations for patient counseling. For most other people, the effect would be indirect and limited to broader public health awareness.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Transplant patients and prospective recipients Supporters would argue that patients deserve clear, understandable information before agreeing to procedures involving human cells and tissues. Better education can help people recognize risks, ask informed questions, and make decisions that match their medical needs and values.
- Clinicians and hospital educators Many providers want reliable federal materials that explain safety, appropriate use, and follow-up considerations. A national campaign can reduce inconsistent messaging and make counseling more standardized across health systems.
- Public health and patient-safety advocates They would view the bill as a low-burden way to improve informed consent and reduce harm from misunderstanding or misinformation. Education can be especially useful in areas where products are promoted with confusing or overstated claims.
- Medical product manufacturers Some manufacturers may worry that a federally sponsored campaign could emphasize risks more than benefits, affecting patient confidence and demand. They may also dislike federal messaging that could increase scrutiny of product claims or marketing practices.
- Small clinics and procedure providers Providers may object if the campaign creates extra counseling expectations or documentation burdens without additional funding. They could also be concerned that more public awareness will raise patient anxiety and make routine procedures harder to discuss.
- Budget-conscious policymakers Opponents may question whether a nationwide campaign is the best use of federal resources compared with direct clinical oversight or research. They may prefer narrower interventions if they believe education alone will have limited effect.
Key Implications
-
““conduct a national, evidence-based education campaign””
HHS would be tasked with creating a broad public-health outreach effort grounded in medical evidence. That means educational materials, outreach, or provider guidance would need to reflect current science rather than promotional messaging.
-
““increase public and health care provider awareness””
The bill targets both patients and clinicians, so its effects would extend beyond public advertising. It is meant to influence what people know before a procedure and what providers explain during care.
-
““potential risks and benefits””
The campaign would not be a one-sided warning or endorsement; it would have to explain both sides of these transplants. In practice, that could help patients compare possible medical benefits against safety concerns, uncertainty, or complications.
-
““human cell and tissue products transplants””
This language points to a specific category of medical products and procedures, not all organ transplants or all medical devices. The practical reach is concentrated among patients and clinicians who encounter these products in surgery, regenerative medicine, or related care.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- S 4885
- Congress
- 119th Congress
- Official title
- A bill to require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
- Policy area
- Healthcare
- Latest action
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (June 24, 2026)
- Last updated
- June 25, 2026
Latest Status
June 24, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.